New Jersey, United States - Verified Market Research recently published a research report
Job Updates: Graduates Vacancy at Novartis
Blogs | | Wow. It’s been an interesting couple of weeks on the industry side of eye care, eh?
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Many thanks to all those who turned up at the EUBIO e…
Novartis had asked the justices to suspend a lower court’s ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company’s third highest-selling drug last year with $2.8 billion in sales. Exclusive-NHS drafts stricter oversight of trans youth care England’s National Health…
Novartis said on Thursday that it would cut up to 400 jobs in Ireland, or about a quarter of its workforce there, as part of a previously announced restructuring programme that will cut 8,000 jobs globally.
Novartis will IPO its generic division and we estimate a lower Sandoz valuation (still at a premium compared to its peers). Click here to read our analysis.
| October 13, 2022
Through the Avoidable Blindness Program, Novartis is working with partners to strengthen eye health in sub-Saharan Africa. Oct 13, 2022 ... | October 13, 2022
EQS-News: EQS Group AG / Key word: Conference Record: Over 7,500 participants from 140 countries at Europe’s largest compliance conference / Novartis AG honored with ‘ECEC Award 2022’... | October 13, 2022
The Complement 3 Glomerulopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period.
The Tendonitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching
Novartis 2022: Innovative medicines focus – PharmaLive PharmaLive
Novartis AG (NVS) Stock Falls -3.32% This Week: Is It a Good Pick?
Pune, Oct. 11, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Influenza Medication Market is expected to clock US$ 1510 million by 2030 and to grow at a CAGR of
WASHINGTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Global multiple sclerosis drugs market size was $25.1 Billion in 2021 and is estimated to generate revenue...
The 2022 Outcomes Creativity Index: Pharma companies aren't afraid to go there – PharmaLive PharmaLive
Allied Market Research published a report, titled, “Cancer Gene Therapy Market ?? ??????? (???? ??????? ?????????????, ????????? ???????????, ???? ????????), ??
In a research note published on Friday, analysts working for Deutsche Bank Aktiengesellschaft decreased their target price for Novartis (NYSE:
A Novartis-funded analysis gives the Novaritis MS drug the nod based on a model using efficacy and safety data.